MS and Demyelinating Disorders

Role of Ocrelizumab in Europe for Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Ocrelizumab for the Treatment of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Role of Siponimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Treating With Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Clinical Trials for Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

The Use of Glatiramer Acetate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

The Use of Interferon in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

First-Line Therapies for Relapsing Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Clinically Isolated Syndrome Versus Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

MOG-IgG in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Differential Diagnosis of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Closing the Treatment Gap in Progressive MS

Tori Rodriguez, MA

August 29th 2020

FDA Approves Ofatumumab, EVT Effective in Late Presenting Stroke, Rimegepant Safe With CGRP Antibodies

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

August 29th 2020

NeurologyLive Friday 5 - August 28, 2020

Neurology News Network for the week ending August 29, 2020.

August 28th 2020

Approaching Multiple Sclerosis With a Global Perspective

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

August 26th 2020

Satralizumab Approved, Epilepsy Surgery Cost-Effective, FDA Approves DMD Treatment Viltolarsen

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

August 22nd 2020

NeurologyLive Friday 5 — August 21, 2020

Neurology News Network for the week ending August 22, 2020.

August 21st 2020

Ofatumumab FDA-Approved for Relapsing Multiple Sclerosis Treatment

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

August 20th 2020

Satralizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder

Novartis’ anti-CD20 monoclonal antibody ofatumumab (Kesimpta) is administered once monthly at home, and is expected to be available for those with multiple sclerosis as early as September 2020.

Alicia Bigica

August 15th 2020

Aducanumab BLA Accepted, Risdiplam Receives FDA Approval, Ofatumumab Lower ARRs Than Teriflunomide

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

August 15th 2020

NeurologyLive Friday 5 — August 14, 2020

Neurology News Network for the week ending August 15, 2020.

August 14th 2020

Personal Social Networks Associated With Physical Function in Multiple Sclerosis

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Marco Meglio

August 12th 2020

Sustained Immunotherapy May Improve Secondary Progressive MS Disability Outcomes

Larger social network effective size correlated with better physical function, while network constraint correlated with worse physical function in those with multiple sclerosis.

August 11th 2020

Ofatumumab Superior to Teriflunomide in ARR Reduction for Multiple Sclerosis

A cohort study showed that those with relapse activity who received DMTs accounted for a greater percent of time with a reduced Multiple Sclerosis Severity Score progression slope during SPMS.

August 10th 2020

NeurologyLive Friday 5 — August 7, 2020

The full data from the ASCLEPIOS I and II trials suggest that the Novartis agent ofatumumab is superior to teriflunomide in reducing annualized relapse rates and other measurements of disease progression in MS.

August 7th 2020

Tweet Chat Highlights: Mental Health in Neurology

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Marco Meglio

August 5th 2020

NeurologyLive Friday 5 — July 31, 2020

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

July 31st 2020

CMSC Announces a Virtual Summer Celebration on August 3rd

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

July 30th 2020